What Avidity Biosciences Phase 1/2 MARINA results reveal about the future of DM1 drug development
NEJM publication of Avidity Biosciences delpacibart etedesiran data raises new questions for DM1 treatment. Discover what this changes next.
Why Avidity is spinning off Atrium Therapeutics before the Novartis acquisition closes
Avidity Biosciences sets spin-off record date for Atrium ahead of Novartis deal. Find out what this carve-out reveals about RNA platform risk and M&A strategy.